Wockhardt soared 13.64% to Rs 780 after the company's experimental antibiotic, Zaynich, successfully treated a US cancer patient with a chronic thigh infection caused by extremely resistant bacteria. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
